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Background: Transcatheter arterial chemoembolization (TACE) is recommended as the ﬁrst-line therapy
for unresectable hepatic carcinoma (HCC). Serious complications such as hepatic abscess and hepaticKey words:
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decompensation are well known, but rupture of HCC after TACE is a rare complication.
Objective: The aim of this study was to identify the associated risk factors and the outcomes resulting
from ruptured HCC after TACE.
Methods: A retrospective analysis was performed in 6 patients who experienced ruptured HCC
after TACE.
Results: All patients underwent chemoembolization after superselective catheterization of the appro-
priate hepatic artery. The interval between the treatment of TACE and ruptured HCC was 6 to 17 days
(mean [SD] 10.33 [4.08] days). Common features in ruptured HCC were large tumor size, location of the
tumor adjacent to liver capsular membrane, and complete occlusion of the tumor feeding artery,
especially in those with a large amount of iodized oil plus polyvinyl alcohol particles. Two patients
underwent emergency embolization, and 4 patients received conservative treatment. Except for
2 patients treated conservatively who died 45 and 68 days after ruptured HCC with hepatic
decompensation, the other 4 patients survived to the 6-month follow-up.
Conclusions: Ruptured HCC after TACE is a rare but serious complication. Large tumor size, location of
the tumor adjacent to the liver capsule, and complete occlusion of the feeding artery may be
predisposing factors. More research is needed to examine which patients presenting with ruptured
HCC after TACE would beneﬁt from conservative or emergency arterial embolization procedures.
& 2013 . The Authors. Published by Elsevier Inc. Open access under CC BY license.Introduction
Hepatic carcinoma (HCC) is one of the most common malig-
nant tumors and the third leading cause of cancer mortality in the
world.1 Transarterial chemoembolization (TACE) is one of the
most common treatment modalities, being a palliative and pre-
operative method for patients with HCC who are considered to be
unsuitable candidates for surgery.2 Although satisfactory survival
results can be achieved with TACE, it is associated with complica-
tions causing signiﬁcant morbidity and mortality. Numerous
publications describe minor complications associated with TACE
in 10% to 12% of patients.3–8 These include postembolization
syndrome (fever, abdominal pain, nausea, and vomiting),ier Inc.
partment of Interventional
ated With Nanjing Medical
Province, China 213003.
ang).
Open access under CC BY liceimpaired liver function, and leukocytopenia.3,6 Although these
are common, there are very few reports of severe post-TACE
complications in the literature.6–8 Major complications include a
3% rate of irreversible liver failure and liver abscess, upper
gastrointestinal bleeding, bile duct complications, acalculous
cholecystitis, pulmonary embolism, spasm or occlusion of the
hepatic artery, and acute renal failure. Ruptured HCC after TACE
has rarely been reported. Here, we report our experience with
ruptured HCC post-TACE in 6 patients.
Patients
Six consecutive patients (all men; 45–67 years of age, mean
[SD] age, 57.83 [8.01] years) fulﬁlled diagnostic criteria for
ruptured HCC after TACE, as demonstrated by Doppler ultrasound
and computed tomography scan or paracentesis, were referred to
our center fromMay 2008 to May 2011. The mean (SD) tumor size
was 13.17 (2.79) cm (range, 9.0–16.0 cm). Two patients (33.3%)
had Child-Pugh grade A hepatic impairment, and the remaining
4 patients (66.7%) had hepatitis B grade impairment. All patients
provided signed informed consent.nse.
Table I
Clinical parameters and treatment outcome.
Variable Patient
1 2 3 4 5 6
Age, y 45 61 53 57 64 67
HBsAg þ  þ þ  
Cirrhosis Yes No Yes No No No
Tumor size, cm 9 13 11 14 16 16
Location (lobe) Right Right Right þ left Right þ left Right þ left Right þ left
Near liver capsule Yes Yes Yes Yes Yes Yes
Tumor capsule No Yes No Yes Yes Yes
Embolism material LþG LþGþP LþP LþP LþP LþG
Amount of iodized oil, mL 20 18 20 25 27 30
PVTT No No Yes Yes No No
Interval between TACE and rupture, days 10 6 7 9 17 13
Outcome Died Alive Died Alive Alive Alive
G, gelatin sponge particles; HBsAg, surface antigen of hepatitis B; L, iodized oil; P, polyvinyl alcohol particles; PVTT, portal vein tumor thrombi; TACE, transcatheter arterial
chemoembolization.
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A retrospective analysis was performed of the patients who
underwent chemoembolization from May 2000 to December
2012. All patients were regularly followed at outpatient clinics.
alpha-fetoprotein, Doppler ultrasound, or computed tomography
scan was performed 1, 3, and 6 months post-TACE. The clinical
parameters and radiological features of the tumor in patients with
rupture were reviewed.Results
All patients underwent chemoembolization with a calculated
dose of oxaliplatin (100–150 mg) and hydroxycamptothecin
(8–10 mg) based on body weight and liver function after super-
selective catheterization of the appropriate hepatic artery.
A mixture of pirarubicin and iodized oil* (10 mg pirarubicin and
10 mL iodized oil) was injected into the arterial branches until
hemostasis was achieved (18–30 mL; mean, 23.3 mL). Gelatin
sponge particles were used in patients whose tumor had a rich
blood supply.
In our study, 6 patients had ruptured HCC after TACE, and the
interval between the TACE treatment and ruptured HCC was 6 to
17 days (mean [SD], 10.33 [4.08] days). The symptoms and signs
of rupture include sudden onset of severe abdominal pain in all
patients and the presence of blood in the peritoneal cavity in the
endemic area in 4 patients. None had radiological evidence of
arteriovenous ﬁstula, coagulopathy, sepsis, or toxicity from
TACE. Two patients had emergency embolization, and the
remaining 4 patients received conservative treatment (medica-
tions for pain relief, hemostasis and energy input, and rest).
Except for 2 patients treated conservatively who died 45 and 68
days after ruptured HCC with hepatic decompensation, the other
4 patients survived to a 6-month follow-up in stable condition.
The clinical parameters and treatment outcomes are summar-
ized in Table I.Discussion
Rupture of HCC after TACE is a life-threatening condition that
may cause severe bleeding and hypotension, especially in* Trademark: Lipiodols (Guerbet, Cedex, France).cirrhotic patients who have coagulation deﬁciencies. Therefore,
the mortality rate of this catastrophic event is very high. It is
important to identify ways to reduce the mortality associated
with ruptured HCC after TACE.
The mechanism of rupture of HCC after TACE is not fully
understood. It is presumably due to tumor and capsular necrosis,
increased pressure inside the tumor, vascular injury during TACE,
or inﬂammation secondary to the chemotherapeutic agents.9 In
addition, several factors such as direct trauma, high pressure due
to edema of the tumor, erosion of a vessel, occlusion of the
hepatic veins by tumor thrombus, and coagulopathy have been
accepted as causes.10 A peripherally located tumor has been
observed in several studies to rupture more easily than one
surrounded by normal parenchyma.11,12 The size and degree of
extrahepatic protrusion have also been found to be predictive of
rupture risk.11–13 It had been reported that large tumor size or
extracapsular extension of the tumor appeared to be a predispos-
ing risk factor.9,11,12 Because typically HCC is a hypervascular
tumor that contains many abnormal blood vessels, any small
increase in vascular load owing to portal hypertension or
mechanical injury may result in tears in the vessel wall producing
a hematoma. Moreover, the arterial wall is probably not normal in
patients with portal hypertension because the incidence of
visceral artery aneurysms is 2% to 4% in patients with cirrhosis.9
Tumor necrosis caused by TACE may be exaggerated by a
secondary infection. Necrosis and the presence of hematoma will
result in increased intratumoral pressure causing rupture.9
Ruptured HCC after TACE should be suspected in patients
presenting with sudden onset of severe abdominal pain, abdom-
inal distention, shock, and the presence of blood in the peritoneal
cavity in an endemic area.14 Diagnosis could be conﬁrmed by
paracentesis and angiography. As seen in our study, all 6 patients
presented with sudden onset of severe abdominal pain, and in
4 patients, blood was present in the peritoneal cavity in an
endemic area.
The common features in the 6 patients with ruptured HCC in
our study were large tumor size, location of tumors adjacent to
the liver capsule, and the use of a large amount of iodized oil plus
polyvinyl alcohol particles to completely embolize the artery
feeding the tumor. These features may be predisposing factors
in ruptured HCC after TACE.
The primary objective in the management of these patients is
to achieve hemostasis by surgery, embolization, or conservative
methods. The mortality and morbidity rates are high among
patients with ruptured HCC because these patients usually have
Z. Jia et al. / Current Therapeutic Research 74 (2013) 41–43 43a poor liver reserve and advanced disease. In our experience,
repeat embolization can be performed to stabilize the patient’s
condition and the tumor in patients whose blood pressure is
unstable, and conservative treatment can be used for patients
whose blood pressure is stable after ruptured HCC after TACE to
get long-term relief.Conclusions
Ruptured HCC after TACE is a rare but potentially life-
threatening complication. Large tumor size, location of tumors
adjacent to the liver capsule, and complete occlusion of the tumor
feeding artery, especially in patients with a large amount of
iodized oil plus polyvinyl alcohol particles may be predisposing
factors for HCC rupture after TACE. Further prospective research is
required to fully understand its mechanism.Acknowledgments
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